SCHEMBL1146360

SCHEMBL1146360

c1cc2cc(-c3ccc(OC4CCN5CCCC4C5)nc3)ccc2[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 9/20 0.57
CHRNB2 P17787 7/20 0.52
CHRNA4 P43681 7/20 0.52
CHRNB4 P30926 6/20 0.52
CHRNA3 P32297 6/20 0.52
HTR3A P46098 1/20 0.45
KCNH2 Q12809 3/20 0.42
MAP3K11 Q16584 2/20 0.40
HRH3 Q9Y5N1 1/20 0.40
ABL1 P00519 1/20 0.38
DYRK3 O43781 1/20 0.38
CCNT1 O60563 1/20 0.38
CDK9 P50750 1/20 0.38
CDK5 Q00535 1/20 0.38
DYRK1A Q13627 1/20 0.38
CDK5R1 Q15078 1/20 0.38
DYRK2 Q92630 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
LRRK2 Q5S007 1/20 0.37
CYP17A1 P05093 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2484210 1.00 CHRNA7 (0.57) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL1146092 1.00 CHRNA7 (0.57) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL2486350 1.00 CHRNA7 (0.57) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL1146363 1.00 CHRNA7 (0.57) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL1146326 1.00 CHRNA7 (0.57) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL1908561 1.00 CHRNA7 (0.57) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL416173 1.00 CHRNA7 (0.57) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL412336 0.90 CHRNA7 (0.52) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL8266486 0.90 CHRNA7 (0.52) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL1146038 0.90 CHRNA7 (0.52) CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1761533-B1 1-AZA-BICYCLO[3.3.1]NONANES NOVARTIS AG (CH) 2011-04-20 EP claimed
US-9475811-B2 1-aza-bicyclo[3.3.1]nonanes NOVARTIS AG (CH) 2016-10-25 US disclosed
US-20150087650-A1 1-AZA-BICYCLO[3.3.1]NONANES NOVARTIS AG (CH) 2015-03-26 US disclosed
US-8933090-B2 1-aza-bicyclo[3.3.1]nonanes NOVARTIS AG (CH) 2015-01-13 US disclosed
EP-1966209-B1 [ 1H- INDOL- 5 -YL) -HETEROARYLOXY] - (1-AZA-BICYCLO [3.3.1] NONANES AS CHOLINERGIC LIGANDS OF THE N-ACHR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENERATIVE DISORDERS NOVARTIS AG (CH) 2011-10-19 EP disclosed
EP-2332537-A1 Combinations of nicotinic acetylcholine alpha 7 receptor agonists Novartis AG (CH) 2011-06-15 EP disclosed
EP-1761533-B1 1-AZA-BICYCLO[3.3.1]NONANES NOVARTIS AG (CH) 2011-04-20 EP disclosed
US-20110034475-A1 1-AZA-BICYCLO[3.3.1]NONANES NOVARTIS AG 2011-02-10 US disclosed
US-20100125063-A1 COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS NOVARTIS AG 2010-05-20 US disclosed
EP-2135609-A1 Combinations of nicotinic acetylcholine alpha 7 receptor agonists Novartis AG (CH) 2009-12-23 EP disclosed
US-20080306081-A1 Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists NOVARTIS AG (CH) 2008-12-11 US disclosed
US-20070249657-A1 1-Aza-Bicyclo3.3.1Nonanes NOVARTIS AG (CH) 2007-10-25 US disclosed
EP-1809285-A1 COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS Novartis AG (CH) 2007-07-25 EP disclosed
WO-2006048294-A1 COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS NOVARTIS AG (CH) 2006-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125063-A1 COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS CHRNA7, CHRNA4, CHRNA10 CHRNA7 1/4885CHRNB2 13/4885CHRNA4 2/4885
US-20070249657-A1 1-Aza-Bicyclo3.3.1Nonanes CBR3, CBR1, HCAR3 CHRNA7 119/4885CHRNB2 710/4885CHRNA4 46/4885
US-20110034475-A1 1-AZA-BICYCLO[3.3.1]NONANES CBR3, CBR1, HRH4 CHRNA7 208/4885CHRNB2 845/4885CHRNA4 55/4885
US-20080306081-A1 Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists CHRNA7, CHRNA4, CHRNA10 CHRNA7 1/4885CHRNB2 13/4885CHRNA4 2/4885
US-20150087650-A1 1-AZA-BICYCLO[3.3.1]NONANES CBR3, CBR1, ADCY3 CHRNA7 228/4885CHRNB2 992/4885CHRNA4 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.